BeiGene cancer drug fails in study against AbbVie: J&J's Imbruvica

- BeiGene Ltd said on Monday a late-stage trial failed to show that its cancer treatment Brukinsa was superior to Imbruvica, a rival drug from Johnson & Johnson and AbbVie Inc. The results come merely a month after BeiGene scored a win with Brukinsa’s approval to treat patients with mantle cell lymphoma, who have received at least one prior therapy.

“It is unlikely that we would do other trials, I think that there’s potential that with longer follow up this trial in and of itself could suffice,” Eric Hendrick, chief adviser at BeiGene, told Reuters. Like Imbruvica, Brukinsa belongs to a class of drugs called Bruton’s tyrosine kinase inhibitors. It also competes against AstraZeneca Plc’s Calquence, another BTK inhibitor.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Stress, Sadness Really Can Break Your HeartBroken heart syndrome doesn't just happen after a loved one or a pet dies. Medical treatments, job loss, and other major life stressors have been linked to the condition too. And losing a loving pet🐕 Wtf yall post this 2 to 3 times a week. Nothing to report 🤦🏽‍♀️ alaurabeatriz
Source: WebMD - 🏆 709. / 51 Read more »